What is HC Wainwright’s Estimate for Pharvaris Q3 Earnings?

Pharvaris N.V. (NASDAQ:PHVS) – Analysts at HC Wainwright decreased their Q3 2026 EPS estimates for Pharvaris in a research note issued on Friday, August 14th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($0.92) for the quarter, down from their prior estimate of ($0.76). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Pharvaris’ current full-year earnings is ($3.08) per share. HC Wainwright also issued estimates for Pharvaris’ Q4 2026 earnings at ($0.98) EPS, FY2026 earnings at ($3.41) EPS, Q1 2027 earnings at ($0.99) EPS, Q2 2027 earnings at ($0.89) EPS, Q3 2027 earnings at ($0.77) EPS, FY2027 earnings at ($3.30) EPS, FY2028 earnings at ($0.56) EPS and FY2029 earnings at $3.09 EPS.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06).

PHVS has been the topic of a number of other reports. Wells Fargo & Company started coverage on Pharvaris in a research note on Wednesday, July 15th. They set an “overweight” rating and a $55.00 price target on the stock. Wall Street Zen downgraded Pharvaris from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. UBS Group set a $74.00 target price on Pharvaris in a research report on Wednesday, May 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a report on Friday, July 17th. Finally, Citigroup reissued a “market outperform” rating on shares of Pharvaris in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Pharvaris has an average rating of “Moderate Buy” and an average price target of $51.08.

Pharvaris Price Performance

Shares of PHVS opened at $35.32 on Tuesday. The stock has a 50-day moving average of $33.79 and a 200-day moving average of $30.17. The company has a market cap of $2.31 billion, a PE ratio of -11.58 and a beta of -2.31. Pharvaris has a one year low of $20.65 and a one year high of $36.93.

Insider Activity

In related news, CEO Berndt Modig sold 2,291 shares of Pharvaris stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $31.07, for a total transaction of $71,181.37. Following the transaction, the chief executive officer owned 135,209 shares of the company’s stock, valued at $4,200,943.63. The trade was a 1.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Anne Lesage sold 27,872 shares of the company’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $35.48, for a total value of $988,898.56. Following the sale, the insider owned 58,750 shares of the company’s stock, valued at $2,084,450. This trade represents a 32.18% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 156,030 shares of company stock worth $5,304,914.

Institutional Trading of Pharvaris

Several institutional investors have recently made changes to their positions in the company. venBio Partners LLC purchased a new stake in shares of Pharvaris in the second quarter valued at about $160,569,809,000. Public Employees Retirement System of Ohio purchased a new position in Pharvaris during the second quarter worth about $196,000. Seven Fleet Capital Management LP purchased a new position in Pharvaris during the second quarter worth about $26,782,245,000. Bank of America Corp DE bought a new stake in Pharvaris in the 2nd quarter worth about $4,800,000. Finally, Elmind Capital LP bought a new stake in Pharvaris in the 2nd quarter worth about $18,180,435,000.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.